Aminologics Co., Ltd. Overview
Key identifiers
| Item | Detail | Source |
|---|---|---|
| Legal name | Aminologics Co., Ltd. ((주)아미노로직스) | [S1] |
| Former name | A-Logics Co., Ltd. ((주)에이로직스), renamed Aminologics in September 2009 | [S1] |
| Founding / incorporation date | 3 September 1997 | [S1] |
| Incorporation jurisdiction | Republic of Korea | [S1] |
| Headquarters | 3F Samoh Building, 151 Yeoksam-ro, Gangnam-gu, Seoul, Korea (Tel +82-2-761-4570) | [S1], [S5] |
| R&D centre | 55 Osongsaengmyeong 5-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do (established 8 January 2010) | [S3] |
| Exchange / ticker | KOSDAQ (Korea Exchange): 074430 | [S15] |
| KOSDAQ registration | June 2004 | [S1], [S15] |
| ISIN / CUSIP | — | — |
| Fiscal year end | 31 December | [S13] |
| Shares outstanding | 88.14 million (30 June 2026); 87.83 million from Q4 2015 through Q1 2026 | [S13] |
| Employees | 40 (aggregator figure; reference date not stated) | [S15] |
| Employee trend (3-year) | — | — |
| Auditor | — | — |
| Representative directors (co-CEOs) | Oh Jang-seok and Oh Seong-seok | [S1], [S2] |
| Largest shareholder | Samoh Pharm Co., Ltd. (삼오제약), 31.81% (end-2025) | [S6] |
| Share price | KRW 977 (close, 15 October 2026) | [S13] |
| Market capitalisation | ≈ KRW 86.1 bn (KRW 977 × 88.14 m shares; analyst calculation). Aggregators quoted KRW 88.9–89.5 bn on 14–15 October 2026 using slightly different share counts/prices | [S13], [S17] |
| 52-week range | KRW 855 – KRW 1,940 | [S17] |
| Business scope (as registered) | Manufacture of amino acids, amino acid derivatives and pharmaceutical intermediates; wholesale of active pharmaceutical ingredients | [S1] |
Aminologics is a small Korean specialty-chemicals company that develops and sells non-natural (unnatural) and D-configured amino acids, protected amino acids (Fmoc, Boc, Cbz) and peptide-side-chain building blocks, built on a proprietary chiral-resolution platform it calls ARCA. A second, shrinking segment distributes six active pharmaceutical ingredients in Korea under domestic rights acquired from its parent, Samoh Pharm, in 2015. The company is asset-light: it owns no manufacturing plant and relies on contract manufacturing, principally Samoh's cGMP plant in Osong. Its strategic relevance has risen with global demand for GLP-1 peptide drugs, for which its catalogue now features semaglutide-, liraglutide- and tirzepatide-type side-chain intermediates. Its economic reality, however, is that of a captive technology-and-sales arm of the Samoh group: roughly 77% of 2025 revenue was booked through Samoh, which also controls the board and holds about 32% of the equity.
What the company does
Aminologics operates two reportable business lines: an Amino Acid business and an API (원료의약품, active pharmaceutical ingredient) business [S6], [S7], [S20].
Amino Acid business. After setting up a research institute in the second half of 2009, the company began researching, manufacturing and selling amino acids and amine-type compounds [S9]. It has since developed several dozen unnatural amino acids and D-amino acid derivatives, and has commercialised application materials such as protected amino acids, amino esters and oligopeptides [S9]. Named examples in its own descriptions include D-Serine, D-Phenylalanine and beta-Phenylalanine [S20]. The website catalogue lists 142 products across six families: amino acids and derivatives; Fmoc-protected amino acids; Boc-protected amino acids; Cbz-protected amino acids; Fmoc α-amino acids; and lipids and linkers [S4]. These materials are building blocks for peptide drugs, small-molecule APIs, agrochemicals and other fine chemicals [S14], [S8].
API business. In 2015 Aminologics acquired from its largest shareholder, Samoh Pharm, the domestic Korean business rights to six APIs for KRW 19.0 bn [S6]. It supplies these APIs — used in products for stroke, eye disease, dermatitis and cosmetics — to multiple Korean finished-dosage manufacturers [S20]. The specific API molecules are not named in the sources reviewed.
Business model and revenue model
| Dimension | Characterisation | Basis |
|---|---|---|
| Revenue type | ~100% product sales (amino acid materials and traded APIs); no disclosed service, subscription or licensing revenue | [S6], [S13] |
| Manufacturing model | Outsourced: production through external contract manufacturers, starting in January 2017 with Samoh Pharm's Osong plant; the company has no production facility of its own | [S9], [S7] |
| Sales channels | (1) indirect export via trading/distribution specialists including Samoh Pharm; (2) direct export to end buyers | [S6] |
| Customer types | Global pharmaceutical companies and peptide manufacturers (amino acids); Korean finished-dose pharma companies (APIs) | [S8], [S20] |
| End-markets | Peptide therapeutics (including GLP-1 class), small-molecule pharma intermediates, agrochemicals, sweeteners, cosmetics, research | [S8], [S14], [S5] |
| Value-chain position | Upstream "raw material of the raw material": chiral building blocks sold to API/peptide manufacturers | [S11] |
Company's own description
The company describes itself (paraphrased from its CEO message) as having pursued, since 2009, the development of diverse biomaterials through chiral separation of amino acids based on its ARCA source technology, with the aim of commercialising amino acid technologies that drive both pharmaceutical and fine-chemical industries; it frames its unnatural-amino-acid work as a "first mover" role [S2]. A third-party English summary of its filings describes it as a specialty manufacturer of amino acids and derivatives whose core competency is the proprietary ARCA chiral-resolution platform, an enzymatic process enabling cost-effective production of high-purity chiral amino acids for pharmaceutical, fine-chemical, agrochemical and life-science uses [S14].
Independent characterisation
Aminologics is best understood as a captive specialty-materials sales and development company within the Samoh Pharm group, not as a vertically integrated manufacturer. Three facts define it:
-
Technology without plant. The value proposition rests on process know-how (ARCA and downstream protection chemistry) and a catalogue of 140-plus SKUs, while physical production sits with Samoh's Osong cGMP plant and other CMOs [S7], [S4].
-
Extreme customer concentration through the parent. Sales to Samoh were KRW 17.0 bn in FY2025, or 77.27% of revenue; about 96% of the Amino Acid segment's FY2025 sales of KRW 17.7 bn went to Samoh, which acts as a trading channel to end buyers [S6]. Revenue quality therefore depends on the opacity of Samoh's onward sales.
-
Mix shift to peptide building blocks. The Amino Acid segment rose from 37.4% of revenue in 2021 to 80% in FY2025 (KRW 17.7 bn of 22.0 bn) and 87% in Q2 2026 [S9], [S6], [S12]. The featured catalogue items — e.g., Fmoc-Lys(AEEAc-AEEAc-(γ-Glu-OtBu)-17-t-butoxycarboxyheptadecanoyl)-OH (CAS 1662688-20-1), tBuO-Ste-Glu(AEEA-AEEA-OSu)-OtBu (CAS 1118767-15-9), Fmoc-Lys(Pal-Glu-OtBu)-OH (CAS 1491158-62-3) and 20-(tert-butoxy)-20-oxoicosanoic acid (CAS 683239-16-9) [S4] — are, on structural analysis by this analyst, side-chain intermediates of the semaglutide, liraglutide and tirzepatide type. The company does not publicly name the drugs its materials serve; this mapping is the analyst's inference from chemical structure.
Strategy
Stated strategy (themes paraphrased from company and press sources)
| Theme | Company statement (paraphrased) | Source |
|---|---|---|
| First-mover in unnatural amino acids | Positions ARCA-based unnatural amino acids as foundational technology that will generate future earnings and benefit society | [S2] |
| Expand into higher-value derivatives | Long-term goal (2012) to secure as many unnatural amino acid technologies as possible and expand into higher-value amino acid derivatives | [S10] |
| Peptide raw-material specialist | Seeks to be a specialist developer/seller of amino acid derivatives for fast-growing peptide drugs; markets at CPhI Japan and Europe | [S8] |
| Cost competitiveness | Optimising production processes and cutting overheads to improve manufacturing cost | [S8] |
| Capacity in R&D talent | Pre-emptively expanding research staff to develop and supply high-quality products on time | [S8] |
| ESG supply-chain credentials | Pursuing EcoVadis assessment and ISO certifications (anti-bribery, environment, health & safety) because global pharma customers require them | [S8] |
| Customer-pull product development | Describes a co-growth model in which global customers, having recognised its quality, request new product development | [S20] |
| Reducing parent dependence | Official said the company is considering, long term, how to reduce reliance on Samoh | [S6] |
Initiatives announced in the last 24 months
| Initiative | Date | Detail | Source |
|---|---|---|---|
| KRW 20 bn 4th private CB | Jun 2025 | Proceeds for operating and R&D funds; Samoh took 25% (KRW 5 bn) | [S6] |
| Normalisation of legacy issues | Stated Apr 2026 | Company said the long process of normalising a previously acquired company was concluded with 2025, and past difficulties had largely been resolved | [S6] |
| GLP-1 side-chain portfolio | Visible on website (date of addition not disclosed) | Featured products are acylated-peptide side chains and linkers | [S4] |
No transformation programme, cost programme with quantified targets, new business launch, platform investment or medium-term financial targets were identified. Management guidance: none publicly issued.
Products & Services
Platform technology: ARCA
| Item | Detail | Source |
|---|---|---|
| Name | ARCA (described in a third-party filings summary as "Alanine Racemase Chiral" technology) | [S14] |
| Nature | Enzymatic chiral-resolution/conversion platform | [S14] |
| Claimed advantages | Operates at room temperature and atmospheric pressure; a single technology can produce many unnatural amino acids in optically pure form, avoiding the narrow substrate scope of conventional enzymatic routes and the harsh conditions or resolving-agent recovery of chemical routes | [S3] |
| Sub-systems shown on website | "Shuttle System" and "Conversion System" | [S5] |
| Origin | Domestically developed source technology; licensed from AminoLux (Oct 2009) | [S3], [S1] |
| Positioning (2012) | Management characterised it as the world's first source technology able to mass-produce diverse amino acids with one catalyst, opening the mid/low-price amino acid market as well as the high-price segment | [S10] |
Catalogue structure (Amino Acid segment)
| Product family | Description | Representative products | Target customer | Source |
|---|---|---|---|---|
| Amino Acids & Derivatives | Unprotected D-, L- and non-proteinogenic amino acids | D-Phenylalanine; D-Alanine; D-allo-Isoleucine; D-Serine; S-beta-Phenylalanine; 3-(2-Naphthyl)-D-alanine; 3-(2-Naphthyl)-L-alanine; 3-(3-Pyridyl)-D-alanine; 3-(3-Pyridyl)-L-alanine; 4-Chloro-D-phenylalanine; 4-Chloro-L-phenylalanine | API and peptide manufacturers; agrochemical and fine-chemical makers | [S18], [S20] |
| Boc-protected Amino Acids | tert-Butoxycarbonyl-protected building blocks for peptide synthesis | Boc-D-Phenylalanine; Boc-D-Ser-OH; Boc-D-4-benzoylphenylalanine; Boc-AEEA-OH DCHA (CAS 560088-79-1) | Peptide synthesis (Boc chemistry) | [S18], [S4] |
| Fmoc-protected Amino Acids | Fluorenylmethoxycarbonyl-protected building blocks for solid-phase peptide synthesis | Fmoc-Lys(Pal-Glu-OtBu)-OH (CAS 1491158-62-3); Fmoc-Lys(AEEAc-AEEAc-(γ-Glu-OtBu)-17-t-butoxycarboxyheptadecanoyl)-OH (CAS 1662688-20-1) | Peptide API manufacturers (SPPS) | [S4] |
| CBZ-protected Amino Acids | Benzyloxycarbonyl-protected amino acids | Individual SKUs not itemised in sources reviewed | Peptide and small-molecule synthesis | [S4] |
| Fmoc α-Amino Acids | α-substituted Fmoc amino acids | Individual SKUs not itemised in sources reviewed | Peptide drug developers | [S4] |
| Lipids & Linkers | Fatty-diacid, OEG linker and activated side-chain fragments used in half-life-extended peptides | Pal-Glu(OSu)-OH (CAS 294855-91-7); 20-(tert-Butoxy)-20-oxoicosanoic acid (CAS 683239-16-9); tBuO-Ste-Glu(AEEA-AEEA-OSu)-OtBu (CAS 1118767-15-9); tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu (CAS 1118767-16-0); Octadecanedioic acid mono-tert-butyl ester (CAS 843666-40-0); H-AEEA-AEEA-OH (CAS 1143516-05-5) | GLP-1 and other acylated-peptide API manufacturers | [S4] |
All nine "featured" products on the website are listed with optical purity above 99.5% [S4]. The catalogue totals 142 products, and the company states it develops new products on customer request [S4]. Pricing is not publicly disclosed; launch years per SKU are not disclosed.
Flagship offerings — analyst mapping to end products
| Featured product (CAS) | Analyst's structural interpretation | Confidence |
|---|---|---|
| Fmoc-Lys(AEEAc-AEEAc-(γ-Glu-OtBu)-17-t-butoxycarboxyheptadecanoyl)-OH (1662688-20-1) | Pre-assembled lysine-plus-side-chain building block of the semaglutide type (C18 diacid–γGlu–OEG–OEG) | Analyst inference; company does not name drugs |
| tBuO-Ste-Glu(AEEA-AEEA-OSu)-OtBu (1118767-15-9) and -OH form (1118767-16-0) | Activated semaglutide-type side chain for late-stage acylation | Analyst inference |
| Octadecanedioic acid mono-tert-butyl ester (843666-40-0) | C18 fatty-diacid starting material for semaglutide-type side chains | Analyst inference |
| Fmoc-Lys(Pal-Glu-OtBu)-OH (1491158-62-3); Pal-Glu(OSu)-OH (294855-91-7) | Palmitoyl-γGlu side-chain building blocks of the liraglutide type | Analyst inference |
| 20-(tert-Butoxy)-20-oxoicosanoic acid (683239-16-9) | C20 fatty-diacid fragment of the tirzepatide type | Analyst inference |
This mapping matters because it places Aminologics in the GLP-1 supply chain, which the Korean press cited as the driver of the January 2026 share-price spike [S7].
API segment portfolio
| Item | Detail | Source |
|---|---|---|
| Number of APIs | Six | [S6], [S20] |
| Therapeutic areas | Stroke, eye disease, dermatitis, cosmetics | [S20] |
| Rights scope | Domestic (Korea) business rights | [S6] |
| Acquired from / price | Samoh Pharm, 2015, KRW 19.0 bn | [S6] |
| Customers | Multiple Korean finished-pharma companies | [S20] |
| Carrying value of rights (customer relationships, other intangibles) | KRW 1.96 bn at end-2025 after successive impairments | [S6] |
| Named molecules | — | — |
Financial Narrative
Income statement: notes and sources
Sources: Revenue, operating income and net income FY2021–FY2025 from DART-compiling aggregators [S11], [S12]; FY2025 cost of sales, gross profit, SG&A, EBITDA, pre-tax income and EPS from [S13]. FY2025 revenue is reported as KRW 22.0 bn (+30.9% YoY in IB Tomato's DART-based account; +31.1% in aggregator data — the small difference reflects rounding of the FY2024 base) [S6], [S12].
Margins and growth
Sources: growth rates [S11]; margins calculated by the analyst from [S11], [S12], [S13].
Revenue CAGR: FY2021–FY2025 ≈ -0.9% p.a.; FY2016–FY2025 ≈ +3.3% p.a. (KRW 16.4 bn to KRW 22.0 bn) [S11], analyst calculation. The company's revenue base has, in effect, oscillated between KRW 16 bn and KRW 27 bn for a decade.
Ten-year context: notes and sources
Source: [S11].
Trailing-twelve-month and interim data: notes and sources
Source: [S13] (aggregator annualised series).
Source: [S11]. H1 2026 revenue was therefore ≈ KRW 13.6 bn and operating income ≈ KRW 2.6 bn (analyst sum).
FY2025 cost and below-the-line detail
The derivative losses and interest expense emerged in FY2025 alongside the KRW 20 bn convertible bond.
Balance sheet: notes and sources
Sources: [S13] for assets, current assets, cash and short-term instruments; [S11] for liabilities-to-equity ratio. Equity and liabilities derived by the analyst as Total assets ÷ (1 + ratio); rounding of the ratio introduces error of roughly ±KRW 0.5 bn. At 30 June 2026 total assets were KRW 89.71 bn and current assets KRW 70.04 bn [S13].
Cash flow: notes and sources
Source: [S11]. Structurally, capex should be minimal because the company owns no plant [S7]; the FY2025 increase in cash plus short-term instruments (≈ KRW 17.6 bn) is largely explained by the KRW 20 bn CB issued in June 2025 [S6], [S13].
Ratios
An aggregator reports TTM ROE of 5.41% at 30 June 2026 [S13].
Commentary on trends, inflections and drivers
FY2021–FY2022: peak on an API-heavy mix. FY2021 revenue rose 29.5% and FY2022 a further 19.6% to a record KRW 27.3 bn, with operating margin peaking at 25.6% [S11]. Q1 2022 showed both segments contributing roughly equally (API KRW 3.9 bn, amino acids KRW 4.2 bn) [S9]. The KRW 7.3 bn net loss in FY2022 despite KRW 7.0 bn of operating profit [S12] signals a large non-operating charge; its nature is not documented in the sources reviewed and should be checked against the FY2022 business report (an impairment of the API business rights is a plausible candidate, as is a loss on financial assets).
FY2023–FY2024: API collapse. Revenue fell 23.6% and then 19.6% [S11]. Since amino acid sales exceeded KRW 15 bn in 2023 and were KRW 11.5 bn in 2024 [S8], [S6], while API sales were only KRW 5.3 bn in 2024 [S6], the API segment appears to have contracted from roughly KRW 14 bn (FY2021) to KRW 5 bn. Amino acid sales also dipped in 2024, coinciding with Samoh's share of revenue falling to 66.67% [S6]. Fixed SG&A (≈ KRW 6 bn) on a smaller base drove the FY2024 operating loss of KRW 2.2 bn.
FY2025–H1 2026: amino-acid-led recovery. Amino acid revenue jumped 54% to KRW 17.7 bn, lifting group revenue 31% and operating margin to 16.3% [S6]. Gross margin reached 44.8% for FY2025 and ≈47.4% on a TTM basis to June 2026 [S13], analyst calculation. Q2 2026 was the strongest quarter since the 2022 peak (revenue KRW 8.2 bn, OP KRW 2.0 bn) [S11]. TTM operating margin to June 2026 was ≈20.9% [S13], analyst calculation.
Balance sheet transformed by the CB. Liabilities-to-equity moved from 10% to 50% in FY2025 purely through the KRW 20 bn CB [S11], [S6]; with cash and short-term instruments of ≈KRW 53 bn, the company remains net cash. The cost is (a) CB-related finance costs and derivative volatility in the P&L, and (b) potential dilution of roughly 20.9 million shares (≈23.8% of the pre-conversion share base) at the KRW 957 conversion price (analyst calculation from [S7]).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products / services | Source |
|---|---|---|---|
Amino Acid (아미노산) | Development and sale of unnatural amino acids, D-amino acid derivatives and application materials | Protected amino acids (Fmoc/Boc/Cbz), amino esters, oligopeptides, lipid and linker side-chain building blocks | [S9], [S4], [S20] |
API (원료의약품) | Distribution of six APIs under domestic Korean rights acquired from Samoh Pharm (2015) | APIs used in stroke, ophthalmic, dermatitis and cosmetic products | [S6], [S20] |
Amino Acid | Predominantly Korea (via Samoh) plus direct export | Global pharma/peptide buyers; specific regions not disclosed | [S6], [S8] |
API | Korea | Korea | [S6], [S20] |
Segment revenue (KRW Bn)
| Segment revenue (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Amino Acid revenue (KRW Bn) | 8.5 | — | — | 11.5 | 17.7 |
API revenue (KRW Bn) | 14.3 | — | — | 5.3 | 4.3 |
Total revenue (KRW Bn) | 22.8 | 27.3 | 20.9 | 16.8 | 22.0 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Segment metric | FY2021 | FY2024 | FY2025 |
|---|---|---|---|
Amino Acid share of revenue (%) | 37.4 | 68.5 | 80.5 |
API share of revenue (%) | 62.6 | 31.5 | 19.5 |
Amino Acid YoY growth (%) | — | — | 53.9 |
API YoY growth (%) | — | — | -18.9 |
Sales to Samoh Pharm
| Sales to Samoh Pharm | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Sales to Samoh Pharm (KRW Bn) | 15.9 | 11.2 | 17.0 |
Share of total revenue (%) | 76.08 | 66.67 | 77.27 |
Income statement (KRW Bn)
| Income statement (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 22.8 | 27.3 | 20.9 | 16.8 | 22.0 |
Cost of sales (KRW Bn) | — | — | — | — | 12.16 |
Gross profit (KRW Bn) | — | — | — | — | 9.86 |
SG&A (KRW Bn) | — | — | — | — | 6.26 |
Operating income (KRW Bn) | 4.1 | 7.0 | 1.5 | -2.2 | 3.6 |
EBITDA (KRW Bn) | — | — | — | — | 3.70 |
Pre-tax income (KRW Bn) | — | — | — | — | 3.51 |
Net income (KRW Bn) | 5.4 | -7.3 | 2.4 | -1.6 | 3.5 |
EPS basic (KRW) | — | — | — | — | 40.1 |
Margins and growth
| Margins and growth | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 29.5 | 19.6 | -23.6 | -19.6 | 31.1 |
Gross margin (%) | — | — | — | — | 44.8 |
Operating margin (%) | 18.0 | 25.6 | 7.2 | -13.1 | 16.3 |
EBITDA margin (%) | — | — | — | — | 16.8 |
Net margin (%) | 23.7 | -26.7 | 11.5 | -9.5 | 16.0 |
Income Statement
| Ten-year history (KRW Bn) | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 16.4 | 16.8 | 18.4 | 19.0 | 17.7 | 22.8 | 27.3 | 20.9 | 16.8 | 22.0 |
Operating income (KRW Bn) | 0.8 | 1.1 | 4.2 | -0.8 | 2.5 | 4.1 | 7.0 | 1.5 | -2.2 | 3.6 |
Income Statement (TTM Jun-2025–TTM Jun-2026)
| TTM metric (KRW Bn) | TTM Jun-2025 | TTM Sep-2025 | FY2025 | TTM Mar-2026 | TTM Jun-2026 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 15.90 | 19.51 | 22.02 | 22.67 | 26.15 |
Gross profit (KRW Bn) | 3.95 | 7.63 | 9.86 | 10.23 | 12.39 |
Operating income (KRW Bn) | -1.79 | 1.73 | 3.59 | 3.71 | 5.47 |
EBITDA (KRW Bn) | -1.16 | 2.35 | 3.70 | 2.92 | 5.61 |
Net income (KRW Bn) | -0.94 | 1.95 | 3.52 | 2.25 | 3.15 |
Income Statement and Margin Analysis (%)
| Quarterly results (KRW Bn) | Q1 2026 | Q2 2026 |
|---|---|---|
Revenue (KRW Bn) | 5.4 | 8.2 |
Revenue YoY (%) | 13.9 | 73.1 |
Operating income (KRW Bn) | 0.6 | 2.0 |
Net income (KRW Bn) | 1.1 | 1.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFY2025 Line Item Details
| FY2025 line item | KRW Bn |
|---|---|
Raw materials within cost of sales | 3.03 |
Salaries within SG&A | 3.47 |
Commissions paid | 0.72 |
R&D expense recognised in SG&A | 0.14 |
Depreciation in SG&A | 0.47 |
Finance income | 3.62 |
of which interest income | 1.28 |
of which gain on disposal of financial assets | 1.51 |
Finance costs | 2.73 |
of which interest expense | 0.98 |
of which derivative losses | 1.51 |
Asset impairment (non-operating) | 1.05 |
Income tax expense | 0.00 |
Balance Sheet and Margin Analysis (%)
| Balance sheet (KRW Bn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (KRW Bn) | 55.58 | 57.66 | 56.78 | 84.17 |
Current assets (KRW Bn) | 43.56 | 45.24 | 46.51 | 78.61 |
Cash and cash equivalents (KRW Bn) | 12.73 | 11.99 | 18.88 | 26.45 |
Short-term financial instruments (KRW Bn) | 16.50 | 16.50 | 16.50 | 26.50 |
Liabilities-to-equity ratio (%) | 8 | 6 | 10 | 50 |
Total equity, derived (KRW Bn) | 51.46 | 54.40 | 51.62 | 56.11 |
Total liabilities, derived (KRW Bn) | 4.12 | 3.26 | 5.16 | 28.06 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansAdditional Balance-sheet Items Details
| Additional balance-sheet items | Detail | Source |
|---|---|---|
Net cash, FY2025 (analyst estimate) | ≈ KRW 33 bn (cash 26.45 + short-term instruments 26.50 − CB face 20.0) | [S13], [S6] |
Goodwill | None identified | — |
Intangibles — API business rights | KRW 1.96 bn (end-2025) | [S6] |
Cash flow (KRW Bn)
| Cash flow (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net change in cash (KRW Bn) | 0.1 | 4.2 | -0.6 | 6.8 | 7.4 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 | Basis |
|---|---|---|---|
ROE (%) | -3.0 | 6.5 | Net income ÷ average derived equity; analyst calculation |
ROA (%) | -2.8 | 5.0 | Net income ÷ average total assets; analyst calculation |
Liabilities/equity (%) | 10 | 50 | [S11] |
Net debt/EBITDA (x) | Net cash | Net cash | Analyst calculation |
Interest coverage, OP ÷ interest expense (x) | — | 3.7 | [S13]; largely non-cash CB accretion |
Asset turnover (x) | 0.29 | 0.31 | Revenue ÷ average total assets; analyst calculation |
Share Price History
| Date | Price (KRW) | Context |
|---|---|---|
9 Jun 2022 | 2,745 (intraday) | Rally on unnatural amino acid growth |
30 Jun 2025 | 1,137 | Quarter-end |
30 Sep 2025 | 995 | Quarter-end |
26 Dec 2025 | 915 | Pre-rally |
31 Dec 2025 | 1,194 | Year-end |
6 Jan 2026 | 1,940 (intraday high) | 52-week high |
31 Mar 2026 | 1,364 | Quarter-end |
30 Jun 2026 | 1,136 | Quarter-end |
15 Oct 2026 | 977 | Latest close |
Share Price & Returns
| Period | Return | Basis |
|---|---|---|
Year-to-date 2026 | -18.2% | KRW 1,194 → KRW 977; analyst calculation [S13] |
Since 30 Sep 2025 (~1 year) | -1.8% | KRW 995 → KRW 977; analyst calculation [S13] |
From 6 Jan 2026 intraday peak | -49.6% | KRW 1,940 → KRW 977; analyst calculation [S7], [S13] |
From Jun 2022 level | ≈-64% | KRW 2,745 → KRW 977; analyst calculation [S9] |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation | ≈KRW 86.1 bn | 88.14 m shares [S13] |
P/E (TTM to Jun-2026) | ≈27.3x | Net income KRW 3.15 bn [S13]; analyst calc. |
P/E (FY2025) | ≈24.5x | Net income KRW 3.52 bn [S12]; analyst calc. |
P/B | ≈1.5x | Aggregator PBR 1.53 [S13] |
Enterprise value (approx.) | ≈KRW 53 bn | Mkt cap + CB face KRW 20 bn − cash and short-term instruments KRW 52.95 bn (end-2025); analyst calc. |
EV/Sales (TTM) | ≈2.0x | Analyst calc. |
EV/EBITDA (TTM) | ≈9.5x | EBITDA KRW 5.61 bn [S13]; analyst calc. |
Aggregator P/E range quoted | 28.3x–34.2x | Varying dates/prices [S13], [S12] |
Valuation Multiple History Details
| Valuation multiple history | FY2025 |
|---|---|
Year-end P/E (x) | 29.8 |
Capital Markets
| Item | Detail |
|---|---|
Dividend policy | Not publicly stated |
Historical dividends | An aggregator lists past annual dividends of KRW 30 and KRW 20 per share paid in April of earlier years |
Recent dividends | Aggregators show no dividend yield for the current period |
Buyback authorisations | None identified; aggregator shows no treasury-share ratio |
Moody's / S&P / Fitch ratings | None (unrated issuer) |
Domestic credit ratings | None identified |
Debt instrument | 4th private CB, KRW 20 bn face, issued Jun 2025; Samoh holds KRW 5 bn |
Conversion price | KRW 957 |
Conversion start | 30 Jun 2026 |
Analyst Conclusions
Guidance and consensus
Management provides no financial guidance, and there is no consensus [S17]. The only forward-looking management comments in the public domain are that the normalisation of legacy problems concluded with 2025 and that the company is considering how to reduce dependence on Samoh over the long term [S6].
Bull case
-
Earnings inflection is real and accelerating. TTM operating income reached KRW 5.47 bn to June 2026, up from a KRW 1.79 bn TTM loss a year earlier, on TTM revenue of KRW 26.15 bn — the highest level since FY2022 [S13]. Q2 2026 revenue grew 73.1% [S11].
-
Exposure to the strongest pharma growth vector. The featured catalogue consists of GLP-1-type side chains [S4]; the largest peptide CDMO guides 35–45% growth for 2026 [S21]. A small supplier can grow quickly if a single programme ramps.
-
Downside cushioned by net cash. With ≈KRW 53 bn of cash and short-term instruments against a KRW 20 bn CB (end-2025) [S13], [S6], the implied EV of ≈KRW 53 bn is about 9.5x TTM EBITDA — undemanding if growth persists.
Bear case
-
Revenue is effectively one related-party customer. About 96% of amino acid sales go to Samoh [S6]; the history of the 2015 API-rights purchase (KRW 19.0 bn, now KRW 1.96 bn) [S6] shows that related-party dealings have destroyed minority value before.
-
Dilution overhang caps upside. The KRW 20 bn CB converts at KRW 957 into ≈20.9 m shares, with the share price now only ≈2% above the conversion price [S7], [S13]; holders can convert on any rally.
-
Structural competitive disadvantage. No owned plant, minimal visible R&D spend (KRW 0.14 bn SG&A line, FY2025) [S13], and better-capitalised entrants — Daesang/AMINO GmbH at ~105% utilisation and KRW 26.5 bn quarterly revenue [S23] — make sustained share gains uncertain.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters | Timing |
|---|---|---|
| Q3 2026 report | Tests whether Q2's KRW 8.2 bn revenue is sustainable | ≈14 Nov 2026 |
| CB conversion filings and large-holding reports | Size and pace of dilution; Samoh's post-conversion stake | Ongoing |
| Samoh share of revenue in FY2026 business report | Evidence of direct-export diversification | Mar 2027 |
| Further API-rights impairment | Residual KRW 1.96 bn | FY2026 audit |
| Korean GLP-1 manufacturing announcements | Potential local demand for side chains | Event-driven |
| EcoVadis/ISO completion | Customer-qualification credentials | Not scheduled |
| Disclosure of any long-term supply agreement | Would de-risk revenue visibility | Event-driven |
Analyst verdict
Aminologics is a genuinely interesting technology asset trapped inside an unattractive corporate structure. On the technology side, the evidence is favourable: a domestically developed chiral platform that the company says produces many optically pure unnatural amino acids under mild conditions [S3]; a catalogue that has moved decisively toward the highest-value niche in peptide chemistry — GLP-1-type acylated side chains [S4]; and a financial recovery that, on TTM numbers to June 2026, shows revenue of KRW 26.2 bn and an operating margin near 21% [S13]. A net cash balance sheet [S13], [S6] means the business is not at financial risk.
On the structural side, the evidence is equally clear and less favourable. Roughly 77% of group revenue and about 96% of amino acid revenue run through the controlling shareholder [S6], which also manufactures the products [S7] and fills the board with family members [S7]. Minority shareholders therefore cannot observe end-customer demand, pricing or contract terms, and must trust a related-party channel whose last major asset sale to the company (the 2015 API rights) has been written down by about 90% [S6]. Layered on top is a live KRW 20 bn convertible overhang struck at KRW 957 [S7] — almost exactly today's KRW 977 share price [S13].
The January 2026 episode, in which the shares nearly doubled on second-hand GLP-1 speculation and then gave it all back [S7], [S13], illustrates how this stock trades: on themes rather than on disclosed fundamentals. Our synthesis is that the stock is fairly valued on present information at ≈9.5x TTM EBITDA (EV basis), with asymmetric event risk in both directions. A re-rating would require either disclosure of named end-customers or long-term contracts, or a visible decline in related-party revenue share. Absent those, the CB overhang and governance discount are likely to cap the shares near the conversion price.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role at Aminologics | Other roles / background | Tenure | Source |
|---|---|---|---|---|
Oh Jang-seok (오장석) | Co-Representative Director (co-CEO); board member | Chairman and co-CEO of Samoh Pharm | Start date not disclosed in sources (Samoh control since 2014) | [S1], [S2], [S7] |
Oh Seong-seok (오성석) | Co-Representative Director (co-CEO); board member | Vice Chairman and co-CEO of Samoh Pharm | — | [S1], [S2], [S7] |
Oh Ju-hyung (오주형) | Director | President of Samoh Pharm; eldest son of Oh Jang-seok | — | [S7] |
Oh Seung-ye (오승예) | Director | President of Samoh Pharm; eldest daughter of Oh Seong-seok | — | [S7] |
Byun Il-seok (변일석) | Head of R&D centre | — | — | [S3] |
Kwan-Woong Jo (age 51) | Listed as director | — | — | [S16] |
Sung-Goo Park (age 63) | Listed as director | — | — | [S16] |
Yeon-Jin Kim (age 59) | Listed as director | — | — | [S16] |
Sung-Cheol Park (age 64) | Listed as director | — | — | [S16] |
In-Ho Choi (age 68) | Listed as director | — | — | [S16] |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake | Reference date | Source |
|---|---|---|---|
Samoh Pharm Co., Ltd. | 31.81% | End-2025 | [S6] |
Samoh Pharm (earlier reference) | ~31% | 30 Sep 2025 | [S7] |
Samoh group affiliate (reported as "심오파마켐", likely Samoh Pharmachem) | 0.67% | 30 Sep 2025 | [S7] |
Oh Jang-seok | 0.32% | 30 Sep 2025 | [S7] |
Oh Seong-seok | 0.32% | 30 Sep 2025 | [S7] |
Largest shareholder and related parties (sum) | ≈33.1% | Analyst sum | [S6], [S7] |
Potential: Samoh conversion of KRW 5 bn CB | ≈5.22 m shares | If fully converted at KRW 957 | [S7] |
Competitive Landscape
Key Competitors
| Competitor | Country | Segment overlap | Relative positioning vs Aminologics | Source / basis |
|---|---|---|---|---|
Bachem Holding AG | Switzerland | Protected amino acids, peptide building blocks, peptide APIs (also a potential customer) | Global leader, vastly larger and integrated | [S21] |
AMINO GmbH (Daesang) | Germany/Korea | Pharma- and infusion-grade amino acids | Plant-owning, high utilisation, now backed by Daesang | [S23] |
Daebong LS | Korea | Pharma amino acids (NAC, carbocisteine) and peptides; GLP-1 ambitions | Larger, diversified, own GMP plant | [S22], [S28] |
Ajinomoto | Japan | Pharma amino acids, peptide CDMO | Global integrated leader | — |
Kyowa Hakko Bio (Kirin) | Japan | Pharma and nutrition amino acids | Fermentation-scale leader | — |
Evonik (Rexim) | Germany/France | Pharma-grade amino acids and derivatives | Major global pharma amino acid supplier | — |
Merck KGaA (Novabiochem/MilliporeSigma) | Germany | Fmoc/Boc building blocks | Dominant catalogue supplier to research and development markets | — |
Iris Biotech | Germany | Unnatural and protected amino acids, linkers | Specialist catalogue house | — |
Watanabe Chemical Industries | Japan | Protected amino acids | Specialist Japanese supplier | — |
Senn Chemicals | Switzerland | Amino acid derivatives | Specialist European supplier | — |
Chinese protected-amino-acid and GLP-1 side-chain makers (e.g., Suzhou Highfine Biotech, GL Biochem) | China | Fmoc amino acids, GLP-1 side chains | Price-aggressive, large-scale; principal pricing threat | — |
Peer Comparison FY2025
| Metric | Aminologics (FY2025) | Bachem (FY2025) | Daebong LS (FY2025) | AMINO GmbH (Q2 2026 only) |
|---|---|---|---|---|
Revenue | KRW 22.0 bn | CHF 695.1 m | KRW 102.1 bn | KRW 26.5 bn (one quarter) |
Revenue growth YoY | +31.1% | +14.8% (+19.2% LC) | +8.6% | — |
Operating/EBIT margin | 16.3% (OP) | 24.1% (EBIT) | 7.1% (OP, analyst calc.) | — |
EBITDA margin | 16.8% | 30.9% | — | — |
R&D intensity | ≥0.6% (SG&A line only) | — | — | — |
Own manufacturing | No | Yes | Yes | Yes |
“—” = not publicly disclosed.
Recent Developments
Company events
| Date | Event | Significance | Source |
|---|---|---|---|
| 15 May 2025 | Q1 2025 quarterly report filed | Start of recovery year | [S11] |
| Jun 2025 | KRW 20 bn 4th private CB issued; Samoh subscribed KRW 5 bn; conversion price KRW 957 | Funded liquidity; created ~20.9 m-share overhang | [S6], [S7] |
| 14 Aug 2025 | H1 2025 report filed | TTM revenue still only KRW 15.9 bn at mid-year | [S11], [S13] |
| 14 Nov 2025 | Q3 2025 report filed: 9M revenue KRW 15.5 bn (amino acids 77%) | Confirmed amino acid-led recovery | [S7], [S11] |
| 26 Dec 2025 | Share price closes at KRW 915 | Pre-rally base | [S7] |
| 30 Dec 2025 | Share price jumps to KRW 1,194 | Start of GLP-1-themed rally | [S7] |
| 2 Jan 2026 | Shares rise 20% to KRW 1,438 | Momentum on GLP-1 theme | [S7] |
| 5 Jan 2026 | KRX designates investment warning advance notice; intraday 52-week high KRW 1,825; close KRW 1,681 | Regulatory cooling measure after ~84% five-session gain | [S7] |
| 6 Jan 2026 | Intraday high KRW 1,940 (52-week high); close KRW 1,682; market cap ≈KRW 147.7 bn | Peak valuation; Samoh's stake valued ≈KRW 45.8 bn | [S7] |
| 12 Mar 2026 | Notice of 29th AGM with e-voting via Samsung Securities | Governance | [S5] |
| 23 Mar 2026 | FY2025 business report filed | Revenue KRW 22.0 bn, OP KRW 3.6 bn, NI KRW 3.5 bn | [S14], [S6] |
| 31 Mar 2026 | 29th AGM results; FY2025 settlement notice | Governance | [S14], [S5] |
| 29 Apr 2026 | IB Tomato analysis highlights record dependence on Samoh and API-rights impairments | Raised governance/quality-of-earnings concerns | [S6] |
| 15 May 2026 | Q1 2026 report: revenue KRW 5.4 bn (+13.9%), OP KRW 0.6 bn | Slow start to 2026 | [S11] |
| 30 Jun 2026 | 4th CB conversion window opens | Dilution overhang becomes live | [S7] |
| 10 Jul 2026 | Large shareholding status report filed | Ownership change | [S14] |
| 13 Jul 2026 | Large shareholding status report and officer/major-shareholder ownership report filed | Ownership change | [S14] |
| 14 Aug 2026 | H1 2026 report: Q2 revenue KRW 8.2 bn (+73.1%), OP KRW 2.0 bn; amino acids 87% of Q2 revenue | Best quarter since 2022 | [S11], [S12] |
| 15 Oct 2026 | Share closes at KRW 977, near the bottom of its 52-week range | Rally fully reversed | [S13], [S17] |
Sector events relevant to Aminologics
| Date | Event | Relevance | Source |
|---|---|---|---|
| Dec 2025 – Mar 2026 | Daesang announced (Dec 2025) and completed (Mar 2026) acquisition of 100% of German specialty amino acid producer AMINO GmbH for ≈KRW 50.2 bn | A large Korean food-chemicals group entering high-purity/pharma amino acids — a new domestic competitor with plant capacity | [S23] |
| 12 Mar 2026 | Bachem FY2025: sales CHF 695.1 m (+14.8%); 2026 guidance 35–45% growth in local currency | Confirms strong peptide/GLP-1 demand for upstream materials | [S21] |
| Jul 2026 | Daebong LS selected for a global GMP support programme (≈KRW 0.4 bn) to prepare pharma amino acids for US FDA, partnering with CJ CheilJedang on four essential amino acids | Another Korean listed company moving toward pharma-grade amino acids | [S28] |
| Aug 2026 | AMINO GmbH reported ~105% plant utilisation with Q2 revenue of KRW 26.5 bn within Daesang | Scale gap: one competitor's quarterly revenue exceeds Aminologics' annual revenue | [S23] |



